Top Markets
Coin of the day
Glenmark Life Sciences Limited Glenmark Life Sciences Limited

Glenmark Life Sciences Limited

GLS
Rang in Aktien #7695
Glenmark Life Sciences Limited, an Indian entity established in Mumbai in 2011,... Glenmark Life Sciences Limited, an Indian entity established in Mumbai in 2011, specializes in the creation, manufacturing, and distribution of high-value active pharmaceutical ingredients (APIs). These APIs are utilized across a wide array of chronic therapeutic areas. The company's diverse portfolio includes compounds for managing cardiovascular diseases (e.g., Olmesartan, Rosuvastatin, Amiodarone), central nervous system conditions (such as Oxcarbazepine, Topiramate, Lacosamide), and diabetes (including Glimepiride, Teneligliptin, Linagliptin). Additionally, they produce APIs for pain management (Etoricoxib, Lornoxicam), gastro-intestinal disorders, anti-infective treatments, respiratory ailments, and anti-emetic applications, featuring products like Atovaquone, Fluconazole, and Esomeprazole Magnesium. Beyond API production, Glenmark Life Sciences offers contract development and manufacturing (CDMO) solutions to numerous multinational and specialty pharmaceutical firms. Operating as a subsidiary of Glenmark Pharmaceuticals Limited, the company exports its products worldwide, reaching markets in Europe, North America, Latin America, and Japan.
Aktienkurs
$12.18
Zuletzt synchronisiert: 2025-02-17
Marktkapitalisierung
$1.49B
Veränderung (1 Tag)
4.21%
Veränderung (1 Jahr)
0.00%
Land
IN
Handel Glenmark Life Sciences Limited (GLS)

Kategorie

Aktien-Split-Historie für Glenmark Life Sciences Limited (GLS)
Die Aktie Glenmark Life Sciences Limited (Symbol: GLS) durchlief insgesamt 0 Aktiensplits.
Der letzte Aktiensplit fand am Aug 28, 2026 statt.
Eine GLS-Aktie, die vor dem Aug 28, 2026 gekauft wurde, entspricht heute 0 GLS-Aktien.
Liste der Aktiensplits
Jahr Aktien-Split Multiplikator Kumulierter Multiplikator
Nicht genügend Daten für die angegebenen Daten.
Aktiensplits ähnlicher Unternehmen oder Wettbewerber